Sai Parenteral’s Limited is positioning itself as a manufacturing-led pharmaceutical platform with expanding global relevance. With five operational facilities across India, ongoing investments in regulatory upgrades, and a pipeline of over 500 product dossiers, the company is aligning its growth strategy with the evolving demands of regulated markets. Its upcoming IPO, opening on March 24, reflects not just a capital-raising exercise but a broader push to strengthen capacity, enhance compliance standards, and deepen its presence in international pharmaceutical value chains.
Key highlights
- 5 manufacturing facilities across India with global regulatory approvals
- Australia facility under development with capex of ā¹ 311 crore; Commercialisation in Q4 CY26
- ā¹111 crore capex towards EU-GMP upgrades and expansion
- 500+ product dossiers with pipeline expansion
- IPO size of ā¹408.79 crore including ā¹285 crore fresh issue and ā¹123.79 crore in OFS
In today’s global landscape, manufacturing is increasingly a strategic differentiator—driven by the need for reliability, compliance, and supply chain control. Companies with strong manufacturing capabilities are better positioned to participate in global pharmaceutical supply chains.
Sai Parenteral’s Limited operates five manufacturing facilities across Telangana and Andhra Pradesh, covering injectables and oral dosage forms, with regulatory accreditations including TGA-Australia, WHO-GMP, and PIC/S—enabling it to serve both regulated and semi-regulated markets.
The Company’s manufacturing facility in Adelaide, Australia (via its subsidiary Noumed), is under construction and expected to be operational by December 2026. Together with its TGA-approved facility in India, this dual-platform positions the Company to fulfil demand through in-house manufacturing while catering to MNCs seeking to onshore production in Australia for a more secure supply chain.
A key focus is the upgradation of facilities to EU-GMP standards. The Company plans to utilise ā¹111 crore towards capacity expansion and regulatory upgrades, strengthening its ability to scale operations and support its growing CDMO and export business.
Anil KK, Chairman & Managing Director, SAI Parenteral’s Limited, said:
“Investments in manufacturing and R&D are key to our next phase of growth as we expand into regulated markets.”
Complementing this is a portfolio of 500+ product dossiers across regulated markets, with 60 additional filings planned by FY28. These dossiers enable faster product launches, and strengthen its ability to partner with global pharmaceutical companies.
Together, manufacturing scale and IP depth position Sai Parenteral’s to move beyond pure manufacturing toward a more integrated, globally relevant pharmaceutical platform.
About Sai Parenteral IPO - Opening on March 24
SAI Parenteral’s IPO of ā¹409 crore, comprising fresh issue of ā¹285 crore and an offer for sale (OFS) of ā¹123.79 crore opens from March 24 to March 27.
The price band fixed is at ā¹372-ā¹392 per share. Given the lot size of 38 shares, the minimum investment fo retail investors is ā¹14,896 while non-institutional investors can bid for a minimum of ā¹2,08,544.
Backed by marquee investors, Samarsh Capital (backed by Mr. Mohandas Pai), Dr. B. Bhaskara Rao (MD, KIMS Hospitals), Blue Lotus Capital, Polycab promoters, and Gruhas Proptech (backed by Mr. Nikhil Kamath and Mr. Abhijeet Pai).
